ADVISORY: |
The Supreme Court E-Library will undergo a system
maintenance on March 28-31, 2024 and will be inaccessible during this period. Thank you for your understanding! |
CONTACT: |
Supreme Court of the Philippines Library Services, Padre Faura, Ermita, Manila, Philippines 1000 |
(632) 8524-2706 |
libraryservices.sc@judiciary.gov.ph |
(NAR) VOL. 16 NO. 4 / OCTOBER - DECEMBER 2005
[ BFAD BUREAU CIRCULAR NO. 18, S. 2005, October 12, 2005 ]
NEW ADVISORY ON LABELING SELECTIVE CYCLOXYGENASE -2 (COX -2) INHIBITORS AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
In pursuance to further enhance safe use of selective Cycloxygenase-2 (COX-2) inhibitors and non-steroidal anti-inflammatory drugs (NSAIDS), the BFAD would like to issue the following directives:
1. Companies are instructed to use remedial labeling to their package inserts of the existing stocks.
2. The remedial labels shall include the boxed warning stating absolute contraindications for COX-2 and NSAIDS. Please refer to Annexes A* and B* of BC No. 11, s. 2005.
3. Companies are granted up to 31 March 2006 to exhaust these stocks with remedial labeling.
For immediate compliance of those concerned.
Adopted: 12 Oct. 2005
(SGD.) PROF. LETICIA BARBARA B. GUTIERREZ, MS
Director IV
* Please See NAR 16 Volume 2, page 741.